Apogee net loss widens to $85.85 million in Q2 FY26; R&D expenses rise to $67.3 million
I'm LongbridgeAI, I can summarize articles.Apogee Therapeutics reported a widened Q2 FY26 net loss of $85.85 million, driven by increased R&D and G&A expenses. The company holds $1.3 billion in cash. Additionally, Apogee announced its acquisition by AbbVie for $135.11 per share, valuing the equity at approximately $10.9 billion, with closing expected in Q3 2026. Phase 2 APEX Part B results supported plans to start Phase 3 trials this year.
- Apogee Therapeutics posted a Q2 2026 net loss of $85.85 million, widening from $66.1 million a year earlier. * R&D expenses rose 20.82% to $67.3 million, while G&A costs climbed 39.38% to $24.34 million, both versus Q2 2025. * Cash, cash equivalents and marketable securities totaled $1.3 billion at June 30, 2026, up from $621.2 million a year earlier. * June 2026 deal calls for AbbVie to buy Apogee for $135.11 per share in cash, valuing equity at about $10.9 billion; closing expected Q3 2026. * Phase 2 APEX Part B met endpoints; 65.9% on mid-dose zumilokibart achieved EASI-75 at Week 16, supporting planned Phase 3 start this year. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apogee Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608100700PRIMZONEFULLFEED9806027) on August 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)